AU2005215874B2 - Anti-EpCAM immunoglobulins - Google Patents

Anti-EpCAM immunoglobulins Download PDF

Info

Publication number
AU2005215874B2
AU2005215874B2 AU2005215874A AU2005215874A AU2005215874B2 AU 2005215874 B2 AU2005215874 B2 AU 2005215874B2 AU 2005215874 A AU2005215874 A AU 2005215874A AU 2005215874 A AU2005215874 A AU 2005215874A AU 2005215874 B2 AU2005215874 B2 AU 2005215874B2
Authority
AU
Australia
Prior art keywords
cancer
immunoglobulin
epcam
administration
serum
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2005215874A
Other languages
English (en)
Other versions
AU2005215874A1 (en
Inventor
Mathias Locher
Malte Peters
Nadja Prang
Cornelia Quadt
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Amgen Research Munich GmbH
Original Assignee
Amgen Research Munich GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Research Munich GmbH filed Critical Amgen Research Munich GmbH
Publication of AU2005215874A1 publication Critical patent/AU2005215874A1/en
Application granted granted Critical
Publication of AU2005215874B2 publication Critical patent/AU2005215874B2/en
Assigned to AMGEN RESEARCH (MUNICH) GMBH reassignment AMGEN RESEARCH (MUNICH) GMBH Request to Amend Deed and Register Assignors: MICROMET AG
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
AU2005215874A 2004-02-13 2005-02-09 Anti-EpCAM immunoglobulins Ceased AU2005215874B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US10/778,915 US20050180979A1 (en) 2004-02-13 2004-02-13 Anti-EpCAM immunoglobulins
US10/778,915 2004-02-13
PCT/EP2005/001307 WO2005080428A2 (en) 2004-02-13 2005-02-09 Anti-epcam immunoglobulins

Publications (2)

Publication Number Publication Date
AU2005215874A1 AU2005215874A1 (en) 2005-09-01
AU2005215874B2 true AU2005215874B2 (en) 2011-01-27

Family

ID=34838270

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2005215874A Ceased AU2005215874B2 (en) 2004-02-13 2005-02-09 Anti-EpCAM immunoglobulins

Country Status (23)

Country Link
US (3) US20050180979A1 (cg-RX-API-DMAC10.html)
EP (2) EP1713830B1 (cg-RX-API-DMAC10.html)
JP (1) JP5220315B2 (cg-RX-API-DMAC10.html)
KR (1) KR101236224B1 (cg-RX-API-DMAC10.html)
CN (1) CN1976951B (cg-RX-API-DMAC10.html)
AT (1) ATE437186T1 (cg-RX-API-DMAC10.html)
AU (1) AU2005215874B2 (cg-RX-API-DMAC10.html)
BR (1) BRPI0507660A (cg-RX-API-DMAC10.html)
CA (1) CA2555694C (cg-RX-API-DMAC10.html)
DE (1) DE602005015544D1 (cg-RX-API-DMAC10.html)
DK (1) DK1713830T3 (cg-RX-API-DMAC10.html)
EA (1) EA011951B1 (cg-RX-API-DMAC10.html)
ES (1) ES2328159T3 (cg-RX-API-DMAC10.html)
IL (1) IL177069A (cg-RX-API-DMAC10.html)
MX (1) MXPA06008942A (cg-RX-API-DMAC10.html)
NO (1) NO339364B1 (cg-RX-API-DMAC10.html)
NZ (1) NZ549125A (cg-RX-API-DMAC10.html)
PL (1) PL1713830T3 (cg-RX-API-DMAC10.html)
PT (1) PT1713830E (cg-RX-API-DMAC10.html)
SI (1) SI1713830T1 (cg-RX-API-DMAC10.html)
UA (1) UA87128C2 (cg-RX-API-DMAC10.html)
WO (1) WO2005080428A2 (cg-RX-API-DMAC10.html)
ZA (1) ZA200606083B (cg-RX-API-DMAC10.html)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004068110A2 (en) 2003-01-24 2004-08-12 University Of Utah Methods of predicting mortality risk by determining telomere length
WO2007008943A2 (en) 2005-07-08 2007-01-18 Xencor, Inc. Optimized anti-ep-cam antibodies
RU2434640C2 (ru) * 2006-02-09 2011-11-27 Микромет Аг Лечение метастатического рака молочной железы
EP1865001A1 (en) * 2006-06-08 2007-12-12 Gsf-Forschungszentrum Für Umwelt Und Gesundheit, Gmbh Specific protease inhibitors and their use in cancer therapy
DK2041181T3 (da) * 2006-06-08 2011-08-29 Helmholtz Zentrum Muenchen Specifikke proteaseinhibitorer og deres anvendelse i cancerterapi
CN101970497B (zh) * 2007-04-04 2017-05-10 希格马托制药工业公司 抗‑EpCAM抗体及其用途
ES2433718T3 (es) 2008-12-22 2013-12-12 University Of Utah Research Foundation PCR multiplex monocromática cuantitativa
US20120252022A1 (en) * 2009-09-21 2012-10-04 Paul Walfish Methods and compositions for the diagnosis and treatment of thyroid cancer
EP2819695B1 (en) * 2012-03-02 2018-06-27 Academia Sinica ANTI-EPITHELIAL CELL ADHESION MOLECULE (EpCAM) ANTIBODIES AND METHODS OF USE THEREOF
CN103387988B (zh) * 2012-09-24 2016-01-06 厦门大学 上皮细胞粘附分子的核酸适体EpCAM Ccut及其制备方法
JP6546158B2 (ja) 2013-05-22 2019-07-17 テロメア ダイアグノスティクス インコーポレイテッド 短いテロメアの存在量の測定
CN103275226B (zh) * 2013-06-09 2017-08-29 中国科学技术大学 特异性抗人上皮细胞粘附分子（EpCAM）的单克隆抗体的制备、鉴定及应用
US11046763B2 (en) * 2014-01-08 2021-06-29 The Board Of Trustees Of The Leland Stanford Junior University Targeted therapy for small cell lung cancer
WO2016108954A1 (en) 2014-12-30 2016-07-07 Telomere Diagnostics, Inc. Multiplex quantitative pcr
HUE054131T2 (hu) 2015-11-19 2021-08-30 Revitope Ltd Funkcionális ellenanyag-fragmens-komplementáció nemkívánatos sejtek elpusztítására szolgáló kétkomponensû rendszerben
CN110035768A (zh) 2016-07-26 2019-07-19 泰莎治疗私人有限公司 嵌合抗原受体
WO2020018964A1 (en) 2018-07-20 2020-01-23 Fred Hutchinson Cancer Research Center Compositions and methods for controlled expression of antigen-specific receptors

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998046645A2 (en) * 1997-04-14 1998-10-22 Micromet Gesellschaft Für Biomedizinische Forschung Mbh Method for the production of antihuman antigen receptors and uses thereof
US20030092160A1 (en) * 1999-04-15 2003-05-15 Abraham Bout Recombinant protein production in a human cell

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5853697A (en) * 1995-10-25 1998-12-29 The United States Of America, As Represented By The Department Of Health & Human Services Methods of treating established colitis using antibodies against IL-12
US7605238B2 (en) * 1999-08-24 2009-10-20 Medarex, Inc. Human CTLA-4 antibodies and their uses
BR0209177A (pt) * 2001-05-03 2004-10-05 Merck Patent Gmbh Anticorpo especìfico a tumor recombinante e uso do mesmo
US20030175268A1 (en) * 2002-01-11 2003-09-18 Saint-Remy Jean-Marie R. Method and pharmaceutical composition for preventing and/or treating systemic inflammatory response syndrome
WO2003099205A2 (en) * 2002-05-20 2003-12-04 Abgenix, Inc. Treatment of renal carcinoma using antibodies against the egfr

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998046645A2 (en) * 1997-04-14 1998-10-22 Micromet Gesellschaft Für Biomedizinische Forschung Mbh Method for the production of antihuman antigen receptors and uses thereof
US20030092160A1 (en) * 1999-04-15 2003-05-15 Abraham Bout Recombinant protein production in a human cell

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Lewis et al. Current Opinion in Molecular Therapeutics 2003, 5(4), 433-436 *

Also Published As

Publication number Publication date
NO339364B1 (no) 2016-12-05
NZ549125A (en) 2008-09-26
ZA200606083B (en) 2007-10-31
EP2107071A3 (en) 2009-12-30
EA200601386A1 (ru) 2007-06-29
JP2008500277A (ja) 2008-01-10
EP1713830B1 (en) 2009-07-22
US20070274982A1 (en) 2007-11-29
ES2328159T3 (es) 2009-11-10
PT1713830E (pt) 2009-10-19
EP2107071A2 (en) 2009-10-07
JP5220315B2 (ja) 2013-06-26
IL177069A0 (en) 2006-12-10
ATE437186T1 (de) 2009-08-15
US20120294873A1 (en) 2012-11-22
PL1713830T3 (pl) 2010-01-29
WO2005080428A3 (en) 2005-11-10
CA2555694A1 (en) 2005-09-01
IL177069A (en) 2010-11-30
US20050180979A1 (en) 2005-08-18
NO20064136L (no) 2006-11-07
HK1096103A1 (en) 2007-05-25
DK1713830T3 (da) 2009-10-12
MXPA06008942A (es) 2007-01-26
CN1976951B (zh) 2012-03-14
EA011951B1 (ru) 2009-06-30
UA87128C2 (ru) 2009-06-25
BRPI0507660A (pt) 2007-07-17
KR101236224B1 (ko) 2013-02-22
KR20070009988A (ko) 2007-01-19
WO2005080428A2 (en) 2005-09-01
EP1713830A2 (en) 2006-10-25
SI1713830T1 (sl) 2009-10-31
AU2005215874A1 (en) 2005-09-01
DE602005015544D1 (de) 2009-09-03
CA2555694C (en) 2013-04-16
CN1976951A (zh) 2007-06-06

Similar Documents

Publication Publication Date Title
US20120294873A1 (en) ANTI-EpCAM IMMUNOGLOBULINS
EP3505535B1 (en) Anti-pd1 monoclonal antibody, pharmaceutical composition thereof and use thereof
CN106967172B (zh) 抗ctla4-抗pd-1 双功能抗体、其药物组合物及其用途
WO2020043184A1 (zh) 抗pd-1-抗vegfa的双功能抗体、其药物组合物及其用途
CN101365486B (zh) 使用抗egfr和抗her2抗体的联合治疗
US20110274688A1 (en) Prevention of tumors with monoclonal antibodies against neu
CN114044827B (zh) 低adcc/cdc功能性单抗及其制备方法与应用
WO1994022478A1 (en) PREVENTION OF TUMORS WITH MONOCLONAL ANTIBODIES AGAINST $i(NEU)
CN121108344A (zh) 抗cd3抗体以及其用途
KR20230093282A (ko) 폐암에 대한 lag-3 길항제 요법
WO2023241656A1 (zh) 包含抗cldn18.2抗体的双特异性抗体、药物组合物及用途
JP2023554422A (ja) がんの治療のための多重特異性抗体
WO2025088496A1 (en) Combination of antibody-drug conjugate and anti-pd-1/tim-3 bispecific binding protein
CN112672759B (zh) 抗程序性死亡配体-1(pd-l1)抗体的抗肿瘤用途
HK1096103B (en) Anti-epcam immunoglobulins
WO2023227115A1 (en) A method of treating solid tumor
WO2026052074A1 (zh) 包含抗体偶联药物和免疫检查点抑制剂的药物组合及其应用
TW202432585A (zh) 癌症新輔助治療的組合物及方法
KR20240038204A (ko) Pd-1에 특이적으로 결합하는 항체를 유효성분으로 포함하는 신경내분비 신생물의 예방 또는 치료용 약학 조성물
HK40010330B (en) Anti-pd1 monoclonal antibody, pharmaceutical composition thereof and use thereof

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
DA2 Applications for amendment section 104

Free format text: THE NATURE OF THE AMENDMENT IS: AMEND THE PATENTEE TO READ AMGEN RESEARCH (MUNICH) GMBH .

MK14 Patent ceased section 143(a) (annual fees not paid) or expired